ETF Holdings Breakdown of KYMR

KYMR institutional holdings

The adjusted close for KYMR on 2025-11-12 was 63.53

The following institutional investment holdings of KYMR have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	27,303	USD 1,734,560 0.3%	63.53
2025-11-12	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	21,650 -0.3%	USD 1,375,425 -0.1%	63.53
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	46,605	USD 2,960,816	63.53
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	46,605 0.3%	USD 2,960,816 0.5%	63.53
2025-11-12	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	896	USD 56,923 0.3%	63.53
Total =		143,059	USD 9,088,540

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with KYMR

Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Barclays

Barclays initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a report published on Wednesday, Marketbeat reports. The firm issued an overweight rating and a $60.00 price target on the stock. Other research analysts have also issued research reports about the stock. BTIG Research reiterated a “buy” rating and set a $59.00 […] - 2025-09-18 05:13:29

Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $58.76

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has received an average rating of “Buy” from the nineteen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, fifteen have given a buy recommendation and three have assigned a strong buy recommendation to the company. The […] - 2025-09-08 02:50:52

Kymera Therapeutics (NASDAQ:KYMR) Rating Lowered to Sell at Wall Street Zen

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday. Other analysts have also recently issued reports about the stock. Oppenheimer restated an “outperform” rating and set a $53.00 target price (down from $56.00) on […] - 2025-08-18 04:46:57

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $59.11 Consensus PT from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average recommendation of “Buy” from the twenty brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company. […] - 2025-08-14 02:32:51

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down Following Weak Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report)’s stock price gapped down prior to trading on Monday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $40.62, but opened at $38.16. Kymera Therapeutics shares last traded at $39.34, with a volume of 134,694 shares trading hands. The company reported […] - 2025-08-13 02:17:07

Notable Two Hundred Day Moving Average Cross - KYMR

In trading on Monday, shares of Kymera Therapeutics Inc (Symbol: KYMR) crossed below their 200 day moving average of $39.13, changing hands as low as $36.65 per share. Kymera Therapeutics Inc shares are currently trading off about 2.8% on the day. The chart below shows the one - 2025-08-11 12:49:18

Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Analysts at Morgan Stanley

Morgan Stanley assumed coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research report released on Thursday morning. The brokerage issued an overweight rating and a $70.00 price objective on the stock. A number of other research analysts also recently issued reports on the company. Guggenheim reissued a “buy” rating and issued […] - 2025-07-04 04:59:46

Bvf Partners L. P/Il Buys 317,167 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Bvf Partners L. P/Il purchased 317,167 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 30th. The shares were bought at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the transaction, the director […] - 2025-07-03 05:26:56

Wells Fargo & Company Lowers Kymera Therapeutics (NASDAQ:KYMR) Price Target to $53.00

Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $53.00 in a report released on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock. Other equities analysts have also issued research reports about the company. Wall Street Zen upgraded Kymera Therapeutics from […] - 2025-06-27 04:46:43

Kymera Therapeutics (NASDAQ:KYMR) Upgraded by Bank of America to “Buy” Rating

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was upgraded by research analysts at Bank of America from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday, Marketbeat.com reports. The firm currently has a $51.00 price target on the stock. Bank of America‘s price objective points to a potential […] - 2025-06-04 02:50:56

Kymera Therapeutics (NASDAQ:KYMR) Sees Large Volume Increase on Analyst Upgrade

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) shares saw strong trading volume on Tuesday after JPMorgan Chase & Co. raised their price target on the stock from $57.00 to $64.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. 961,245 shares changed hands during mid-day trading, an increase of 62% from […] - 2025-06-04 02:01:25

Universal Beteiligungs und Servicegesellschaft mbH Invests $4.61 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 114,587 shares of the company’s stock, valued at approximately $4,610,000. Universal Beteiligungs und […] - 2025-06-02 05:36:54

Bank of America Corp DE Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Bank of America Corp DE cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 43.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,260 shares of the company’s stock after selling 48,772 shares during the quarter. Bank of America […] - 2025-06-02 04:38:48

BNP Paribas Financial Markets Makes New $396,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

BNP Paribas Financial Markets acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,838 shares of the company’s stock, valued at approximately $396,000. Several other hedge […] - 2025-05-26 04:24:47

D. E. Shaw & Co. Inc. Lowers Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

D. E. Shaw & Co. Inc. cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 56.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 82,578 shares of the company’s stock after selling 105,619 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Kymera Therapeutics were worth […] - 2025-05-19 05:12:56

Northern Trust Corp Grows Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Northern Trust Corp raised its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 14.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 437,833 shares of the company’s stock after acquiring an additional 53,658 shares during the quarter. Northern Trust Corp’s holdings in Kymera Therapeutics were worth $17,614,000 as of […] - 2025-05-15 05:38:47

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Comerica Bank

Comerica Bank cut its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 45.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 20,631 shares of the company’s stock after selling 17,442 shares during the quarter. Comerica Bank’s holdings in Kymera Therapeutics were worth $830,000 at the end of the most recent reporting […] - 2025-05-14 05:19:05

Guggenheim Reaffirms “Buy” Rating for Kymera Therapeutics (NASDAQ:KYMR)

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Monday,Benzinga reports. They presently have a $52.00 price target on the stock. Guggenheim’s price objective points to a potential upside of 66.99% from the company’s current price. A number of […] - 2025-05-14 03:10:53

Tower Research Capital LLC TRC Increases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Tower Research Capital LLC TRC increased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 95.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,812 shares of the company’s stock after purchasing an additional 2,350 shares during the […] - 2025-05-06 05:16:52

Marshall Wace LLP Sells 110,846 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Marshall Wace LLP decreased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 94.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,835 shares of the company’s stock after selling 110,846 shares during the period. Marshall Wace LLP’s holdings in […] - 2025-05-05 05:04:51

Wells Fargo & Company MN Has $883,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Wells Fargo & Company MN grew its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 51.8% during the fourth quarter, Holdings Channel reports. The firm owned 21,939 shares of the company’s stock after acquiring an additional 7,487 shares during the quarter. Wells Fargo & Company MN’s holdings in Kymera Therapeutics were worth $883,000 […] - 2025-05-01 04:35:02

Franklin Resources Inc. Acquires 8,927 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Franklin Resources Inc. raised its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 30.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 38,367 shares of the company’s stock after acquiring an additional 8,927 shares during the period. Franklin Resources Inc. owned approximately 0.06% […] - 2025-04-15 05:32:48

Alliancebernstein L.P. Cuts Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Alliancebernstein L.P. lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 29.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 88,246 shares of the company’s stock after selling 36,368 shares during the quarter. Alliancebernstein L.P.’s holdings in Kymera Therapeutics were worth $3,550,000 as of its most recent filing with the […] - 2025-04-15 04:50:48

Norges Bank Invests $3.67 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Norges Bank acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 91,231 shares of the company’s stock, valued at approximately $3,670,000. Several other large investors have also bought and […] - 2025-04-11 05:12:59

Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $56.36

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-04-11 03:08:47

Vanguard Group Inc. Acquires 133,546 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 2.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,887,312 shares of the company’s stock after purchasing an additional 133,546 shares during the quarter. Vanguard Group Inc. owned about 0.08% of Kymera Therapeutics worth $196,617,000 […] - 2025-04-07 04:34:48

Teacher Retirement System of Texas Increases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Teacher Retirement System of Texas raised its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 35.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,490 shares of the company’s stock after purchasing an additional 3,026 shares during the period. Teacher Retirement System of Texas’ holdings in Kymera Therapeutics were worth […] - 2025-04-01 04:40:45

Charles Schwab Investment Management Inc. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Charles Schwab Investment Management Inc. lifted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 5.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 387,187 shares of the company’s stock after purchasing an additional 20,346 shares during the quarter. […] - 2025-03-21 05:10:59

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen research firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy […] - 2025-03-14 04:41:01

New York State Common Retirement Fund Has $585,000 Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

New York State Common Retirement Fund cut its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 7.0% during the fourth quarter, Holdings Channel reports. The fund owned 14,549 shares of the company’s stock after selling 1,100 shares during the period. New York State Common Retirement Fund’s holdings in Kymera Therapeutics were […] - 2025-03-05 06:41:05

Back to Listing

Disclaimer